The current idea is that the progression of prostate cancer in the setting of castrate androgen levels is not due to the development of an androgen insensitive tumour clone but rather to the fact that the cancer has evolved mechanisms to escape systemic androgen deprivation while still taking advantage of signalling through AR [6, 13–15, 22]. This evidence concerns the gene AR and prostate carcinoma.